The Liraglutide segment is projected to be the fastest-growing drug category, registering a CAGR of 9.1% from 2026 to 2033, reflecting increasing utilization in both diabetes and obesity treatment applications
doi: 10.1038/s41467-026-71809-x Mondal, Victor, Ross-Munro, Emily, Balasuriya, Gayathri K, Kumari, Ritu, Shearer, Isabelle K, Micic, Andjela, Al Mamun Sohag, Abdullah, Shi, Alan, Barresi, Mikaela, Nisbet, David R, King, Glenn F, Williams, Richard J, Gressens, Pierre, Wong, Flora Y, Cheong, Jeanie L Y, Walker, David W, Tolcos, Mary and Fleiss, Bobbi (2026)
Why genetics matter when you are cost-shopping GLP-1 GLP-1 response varies meaningfully across patients
Firstly, resveratrol decreases the expression of genes that are responsible for encoding the drug-metabolizing enzymes and drug transporters like ABC efflux transporters and proteins like MRP1/ABCC1 that contribute to the elimination of cancer drugs and chemoresistance [220, 221]
Zepbound met the primary endpoint and all five key secondary endpoints in the trial
For metabolic syndrome: 2 grams of MYO twice daily for one year (23)
